Sunday, 25 November 2012

Research: poor sleep

EpubBøe Lunde et al. Poor sleep in patients with multiple sclerosis. PLoS One. 2012;7(11):e49996. doi: 10.1371/journal.pone.0049996. Epub 2012 Nov 14.

BACKGROUND: Poor sleep is a frequent symptom in patients with multiple sclerosis (MS). Sleep may be influenced by MS-related symptoms and adverse effects from immunotherapy and symptomatic medications. We aimed to study the prevalence of poor sleep and the influence of socio-demographic and clinical factors on sleep quality in MS- patients.
 
METHODS: A total of 90 MS patients and 108 sex-and age- matched controls were included in a questionnaire survey. Sleep complaints were evaluated by Pittsburgh Sleep Quality Index (PSQI) and a global PSQI score was used to separate good sleepers (≤5) from poor sleepers (>5). Excessive daytime sleepiness, the use of immunotherapy and antidepressant drugs, symptoms of pain, depression, fatigue and MS-specific health related quality of life were registered. Results were compared between patients and controls and between good and poor sleepers among MS patients.
 
RESULTS: MS patients reported a higher mean global PSQI score than controls (8.6 vs. 6.3, p = 0.001), and 67.1% of the MS patients compared to 43.9% of the controls (p = 0.002) were poor sleepers. Pain (p = 0.02), fatigue (p = 0.001), depression (p = 0.01) and female gender (p = 0.04) were associated with sleep disturbance. Multivariate analyses showed that female gender (p = 0.02), use of immunotherapy (p = 005) and a high psychological burden of MS (p = 0.001) were associated with poor sleep among MS patients.
 
CONCLUSIONS: Poor sleep is common in patients with MS. Early identification and treatment of modifiable risk factors may improve sleep and quality of life in MS.

  
Conclusions say it all. Maybe there are things that can help  imporve this. Time to Investigate further!

3 comments:

  1. How such research gets funded is beyond me. A chat with 15 people at an MS club could have identified these findings. Having a neruo-degenerative disease plays on yor mind = impact on sleep. Addressing neuo-degeneration (to give sufferers stability) = improved sleep. This would also improve mood etc etc. The lesson for all the symptoms is to address progression. The day you can offer neruo-protective treatments and say to aptients that they will now be stable (no more worsening)= you will huge reduction in patients seeking symptomatic treatments.

    ReplyDelete
    Replies
    1. The research was funded by the Norwegian Multiple Sclerosis Competence Centre, Bergen, Norway; and unrestricted grants from Novartis Norway. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

      Delete
  2. improve yourself first

    ReplyDelete

Please note that all comments are moderated and any personal or marketing-related submissions will not be shown.